Antibacterial Effect of Zinc Oxide Nanoparticles on Acinetobacter Baumannii Isolated from Patients with Hospital Acquired Infections in Sohag University Hospitals, Egypt
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Culture specific antibiotic therapy, Antibiotic, Biofilm assessment, nanoparticle zinc oxide.
- Who it may be relevant to
- Registry conditions: Infections, Nosocomial, Infections, Respiratory Tract. Basic parameters: up to 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
A. baumannii is known as the most frequently isolated organism in intensive care units (ICUs), causing a variety of nosocomial infections, including pneumonia, urinary tract infections (UTIs), bacteremia as well as skin and soft tissue infections. These infections are usually associated with high mortality rates ranging between 26% among hospitalized patients and 43% among ICU patients.
Detailed description
Acinetobacter baumannii (A. baumannii) is Gram- negative, aerobic, glucose non-fermentative, non-motile coccobacillus, ubiquitous in nature, and persistent in healthcare settings. It is regarded as a significant opportunistic human pathogen.
This bacterium become a growing problem in hospitals as a predominant multidrug-resistant (MDR) bacterium. Horizontal acquisition of resistance genes is the main factor involved in the emergence of MDR .
There are many mechanisms to confer resistance to different classes of antibiotics in A. baumannii, one of them is multidrug efflux pumps. These efflux pumps are important source of MDR, which export antibiotics from the cell, increasing their antibiotic resistance.
AdeABC is one of the most important efflux systems, belonging to the RND family in Acinetobacter, which plays an important role in the resistance to a broad group of antibiotics; its genes are chromosomal and encode three genes, i.e., AdeB, AdeA, and AdeC, forming an operon in the vicinity. In addition, the expression of AdeABC is done by a two-component system, which includes a response regulator (AdeR) and a sensor kinase (AdeS) .
The ability of Acinetobacter spp. to form biofilm that enables bacterial survival in hospital settings, especially in ICUs, is the most significant contributing factor to their virulence, and this trait is also responsible for their notable antibiotic resistance. Several biofilm-related genes influence antimicrobial susceptibility, suggesting an association between the biofilm-forming ability of Acinetobacter spp. and their antibiotic resistance patterns (MDR/XDR)
Zinc oxide nanoparticles (ZnO NPs) are one of the most important nanoparticles of metal oxides; it is a unique and inorganic materials that can be used in several biological applications (anti-bacterial, anti-inflammatory). ZnO NPs exhibit distinctive properties other than other nanoparticles such as higher solubility, better biofilm penetration and effective drug delivery . ZnO NPs have been reported to have antimicrobial properties such as disrupting the cell membrane of pathogens, accumulating in the cell and producing toxic H2O2 (hydrogen peroxide)
Interventions
- Diagnostic test Culture specific antibiotic therapy
Samples will be cultured on MacConkey agar. Morphological identifications of growth isolates by Gram staining, colony features and conventional biochemical tests. All isolates will be identified to species level using automated bacterial identification systems. - Diagnostic test Antibiotic
Strains confirmed as A. baumannii will be examined for their different antibiotic susceptibility by modified Kirby Bauer\'s disc diffusion method on Mueller Hinton Agar. - Diagnostic test Biofilm assessment
The biofilm formation activity of A. baumannii isolates will be tested using the microtitre plate technique - Diagnostic test nanoparticle zinc oxide
Detection of the effect of ZnO NPs on the biofilm producer MDR A. baumannii strains using the same method - Diagnostic test Molecular detection of antibiotic resistance
\- Evaluation the effect of ZnO NPs on the expression of some efflux pump genes, and biofilm related genes in MDR A. baumannii isolates using Real time PCR technology.
Primary outcome measures
- A. baumannii antibiotic susceptibility profile [Time frame: October 2024 to December 2025]
- Isolation and identification of A. baumannii from different clinical samples [Time frame: October 2024 to December 2025]
- A. baumannii strains which produce biofilm [Time frame: October 2024 to December 2025]
- Ability of ZnO NPs to inhibit the phenomenon of biofilm formation by MDR A. baumannii strains [Time frame: October 2024 to December 2025]
- The effect of ZnO NPs on the expression of some efflux pump genes and biofilm related genes in MDR A. baumannii strains [Time frame: October 2024 to December 2025]
Eligibility criteria
Inclusion criteria
- All patients suffering from infections that can be caused by A. baumannii.
Exclusion criteria
- All patients suffering from infections that aren\'t caused by A. baumannii.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-control
Study locations
Egypt · 1 center
- Sohag university, Faculty of medicine — Sohag
Identifiers
NCT: NCT06628076 · Soh-Med-24-9-1MD